TITLE

Sedation, Sucralfate, and Antibiotic Use Are Potential Means for Protection against Early-Onset Ventilator-Associated Pneumonia

AUTHOR(S)
Tripodi, M. F.; Adinolfi, L. E.; Ragone, E.; Mangoni, E. Durante; Fortunato, R.; Iarussi, D.; Ruggiero, G.; Utiii, R.
PUB. DATE
May 2004
SOURCE
Clinical Infectious Diseases;5/15/2004, Vol. 38 Issue 10, p1401
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
To examine risk factors for early-onset ventilator-associated pneumonia (EOP) in patients requiring mechanical ventilation (MV), we performed a prospective cohort study that included 747 patients. Pneumonia was defined as a positive result for a protected quantitative distal sample. EOP was defined as pneumonia that occurred from day 3 to day 7 of MV. Eighty patients (10.7%) experienced EOP. Independent predictors of EOP were male sex (odds ratio [OR], 2.06; 95% confidence interval [CI], 1.18-3.63), actual Glasgow Coma Scale value of 6-13 (OR, 1.95; 95% CI, 1.2-3.18), high Logistic Organ Dysfunction score at day 2 (OR, 1.12 per point; 95% CI, 1.02-1.23), unplanned extubation (OR, 3.19; 95% CI, 1.28-7.92), and sucralfate use (OR, 1.81; 95% CI, 1.01-3.26). Protection occurred with use of aminoglycosides (OR, 0.36; 95% CI, 0.17-0.76), β-lactams and/ or β-lactamase inhibitors (OR, 0.47; 95% CI, 0.28-0.83), or third-generation cephalosporins (OR, 0.33; 95% CI, 0.16-0.74). Sucralfate use and unplanned extubation are independent risk factors for EOP. Use of aminoglycosides, β-lactams/β-lactamase inhibitors, or third-generation cephalosporins protects against EOP.
ACCESSION #
13077137

 

Related Articles

  • Zyvox.  // Royal Society of Medicine: Medicines;2002, p582 

    This article presents information on Zyvox which is a recently introduced proprietary, prescription-only compound preparation of the antibiotic-like antibacterial agent linezolid. It can be used in the treatment of pneumonia, and skin and soft tissue infections, and is available as tablets or is...

  • Evidence-Based Clinical Practice Guideline for the Prevention of Ventilator-Associated Pneumonia. Dodek, Peter; Keenan, Sean; Cook, Deborah; Heyland, Daren; Jacka, Michael; Hand, Lori; Muscedere, John; Foster, Debra; Mehta, Nav; Hall, Richard; Brun-Buisson, Christian // Annals of Internal Medicine;8/17/2004, Vol. 141 Issue 4, p305 

    Background: Ventilator-associated pneumonia (VAR) is an important patient safety issue in critically ill patients. Purpose: To develop an evidence-based guideline for the prevention of VAR. Data Sources: MEDLINE, EMBASE, and the Cochrane Database of Systematic Reviews. Study Selection: The...

  • Treatment of Community-Acquired Pneumonia (CAP) for 3 Days. Deresinski, Stan // Clinical Infectious Diseases;9/15/2006, Vol. 43 Issue 6, pv 

    The article discusses the research "Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderately severe community-acquired pneumonia: randomized, double-blind study," by R. el Moussaoui and colleagues which attempts to define acceptable shorter...

  • Appropriate antibiotic therapy for ventilator-associated pneumonia and sepsis: a necessity, not an issue for debate. Kollef, Marin H. // Intensive Care Medicine;Feb2003, Vol. 29 Issue 2, p147 

    Focuses on the study that identifies the difference in mortality between patients receiving appropriate and inappropriate therapy for patients with postoperative pneumonia. Use of antibiotic therapy for the disorder; Administration of appropriate antimicrobial therapy; Importance of determinants...

  • Timing of Antibiotics in Patients Hospitalized with CAP. Miller, Karl E. // American Family Physician;1/1/2005, Vol. 71 Issue 1, p171 

    Deals with a study which concluded that antibiotic administration within four hours of arrival at the hospital in patients with community-acquired pneumonia (CAP) had a positive impact on mortality and length of stay. Relationship between early antibiotic administration and survival of such...

  • Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Dupont, H.; Mentec, H.; Sollet, J. P.; Bleichner, G. // Intensive Care Medicine;Feb2001, Vol. 27 Issue 2, p355 

    Objectives: To evaluate the impact of appropriate initial antibiotic therapy (AB) on the outcome of ventilator-associated pneumonia (VAP). Design: Retrospective study (1992–97). Patients and methods: Episodes of VAP diagnosed on both clinical and microbiological criteria after ≥48 h...

  • Antimicrobial Prophylaxis in Febrile Neutropenia. Yoshida, Minoru; Ohno, Ryuzo // Clinical Infectious Diseases;7/15/2004 Supplement 1, Vol. 39, pS65 

    Antibiotics generally considered for antibacterial prophylaxis for immunosuppressed patients are trimethoprim-sulfamethoxazole and the quinolones. Trimethoprim-sulfamethoxazole can significantly reduce infections and is highly effective in preventing pneumonia due to Pneumocystis carinii....

  • Macrolides in cystic fibrosis. Bell, SC; Senini, SL; McCormack, JG // Chronic Respiratory Disease;2005, Vol. 2 Issue 2, p85 

    Macrolide antibiotics have been licensed since the 1950s and have an important role in the treatment of a diverse range of infectious diseases. Macrolide antibiotics have antibacterial activity against grampositive bacteria, some gram-negative bacteria and intracellular pathogens. The spectrum...

  • Azithromycin Extended Release: A Review of its Use in the Treatment of Acute Bacterial Sinusitis and Community-Acquired Pneumonia in the US. Swainston, Tracy; Kean, Susan J. // Drugs;2007, Vol. 67 Issue 5, p773 

    Azithromycin is a macrolide antibacterial agent. The novel microspheres oral extended-release formulation (Zmaxâ„¢) is the first antibacterial drug approved in the US for administration as a single dose in adult patients with mild to moderate acute bacterial sinusitis (ABS) or...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics